We studied thrombin-induced metabolism of phosphoinositide, protein phosphorylation and platelet aggregation in platelets from 32 NIDDM patients and 12 control subjects. To clarify the effect of diet, sulphonylureas, or insulin treatment, the subjects were divided into three groups based on the type of treatment. Thrombin-induced platelet aggregation was measured with an aggregometer. Low-dose thrombin (0.25 U/ml)-stimulated platelet aggregation in diabetic patients was significantly increased compared with the control subjects. Platelet aggregation in the sulphonylurea and insulin groups was significantly lower than in the diet group. On the other hand, in platelets incubated with p2p]orthophosphate, thrombin-induced incorporation of 32p radioactivity into phosphatidic acid (PA) was significantly lower in the sulphonylurea and insulin groups than in the diet group. Thrombin-induced incorporation of [32p] radioactivity into phosphatidylinositol (PIP) for 10 s was significantly higher in the sulphonylurea group than in the diet group. There were no differences in thrombin-induced 47kDa protein phosphorylation between platelets from the diet, sulphonylurea, or insulin groups. These results suggest that sulphonylureas and insulin induce suppression of thrombin-induced activation of phospholipase C, which mediates hydrolysis of PIP and PIP2 and production of PA, which leads to inhibition of platelet aggregation. [Diabetologia (1994) 37: 632-638[ 
and IP3 which induces the rapid release of Ca 2 + from a dense tubular system [1] [2] [3] [4] [5] , and stimulates phospholipase A2 to release arachidonic acid. Diacylglycerol is known to activate protein kinase C [6, 7] , and is effectively phosphorylated to PA, which can then be redirected to PI through cytidine diphosphate-diacylglycerol as shown in Figure 1 . On the other hand, arachidonic acid is oxygenated to produce thromboxane A2 [8] .
Platelet aggregating function in diabetic patients is increased compared with healthy subjects [9, 10] . Moreover, enhanced arachidonic acid release and thromboxane production have been reported in platelets from NIDDM patients [11, 12] . Recently there have been reports [13] [14] [15] focusing on thrombin-induced changes in phosphoinositide metabolism in diabetic patients. Decreased platelet phosphoinositide turnover and enhanced platelet activation in IDDM patients have also been reported [13] . On the other hand, an increased platelet phophoinositide turnover has been observed together with an enhanced platelet aggregating function in NIDDM patients who are being treated with sulphonylureas or insulin [14] . We have also reported that the breakdown of phosphoinositides increases in NIDDM patients with retinopathy and decreases in NIDDM patients with macroangiopathy [15] . However, the patients in these studies were undergoing various diabetic treatments, thereby complicating interpretation of the results of platelet aggregating function and thrombin-induced alteration of phosphoinositide. Fig. 1 . Simplified polyphosphatidylinositol cycles. The PI cycle has PI and DG as common metabolites, and the steps are believed to be controlled by thrombin stimulation. The following abbreviations are used: PI, phosphatidylinositol; PIR phosphatidylinositol-4-monophosphate; PIP2, phosphatidylinositol-4,5-bisphosphate; PA, phosphatidic acid; PC, phosphatidylcholine; DG, diacylglycerol; IP3, inositol 1,4,5-triphosphate; CDP-DG, cytidine diphosphate diacylglycerol; PLC, phospholipase C; PLD, phospholipase D; PKC, protein kinase C
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In this study, we have compared thrombin-induced platelet aggregation, phosphoinositide metabolism and protein phosphorylation in NIDDM patients treated by diet, sulphonylurea or insulin.
Subjects and methods
Subjects. The NIDDM patient group comprised 18 men and 14 women, ranging in age from 40 to 67 years. They were admitted to The Third Department of Internal Medicine, Gifu University Hospital during 1991-1992, and were not being treated with any medication which could affect platelet aggregation. The control subjects had no history of diabetes or any other serious medical condition. All subjects gave their informed consent for participation and the study was approved by the regional Ethics Committee. The diagnosis of diabetes was confirmed according to the criteria recommended by the World Health Organization Expert Committee on Diabetes Mellitus. Glucagonstimulated C-peptide secretion was routinely performed on the diabetic patients to ascertain endogenous insulin secretion. The NIDDM patients were divided into three groups as shown in Table 1 : those treated with diet alone (n = 8, diet group); those treated with diet plus sulphonylureas (n = 12, sulphonylurea group); and those treated with diet plus insulin (n = 12, insulin group). In the diet group, two patients had been diagnosed with diabetic retinopathy (one with background retinopathy and the other proliferative retinopathy), two had been diagnosed with overt nephropathy (microalbuminuria more than 200 btg/min), and, two with macroangiopathy (angina pectoris and aortic calcification, respectively). In the sulphonylurea group, seven patients had been diagnosed with diabetic retinopathy (two with background, one with preproliferative, and four with proliferative retinopathy, respectively), three had been diagnosed with neuropathy with weak patellar and Achilles tendon reflexes, decreased motor nerve conduction velocity, and abnormal expiration/inspiration ratio [16] which was assessed by measuring the ratio of the longest to the shortest R-R interval during deep breathing. Three patients had been diagnosed with nephropathy (proteinuria), and three with macroangiopathy (one with angina pectoris, and two with aortic calcification, respectively). In the insulin group, 10 patients had been diagnosed with diabetic retinopathy (one with background, one with preproliferative, and eight with proliferative retinopathy), 10 had been diagnosed with nephropathy with proteinuria, seven with neuropathy with abnormal tendon reflex, motor nerve conduc- Values are given as mean + SD. ap < 0.01, insulin or sulphonylurea group vs diet group; FBG, fasting blood glucose; TG, triglycerides 
Preparation of [32p]-labelled human platelets: Fresh blood was
obtained from the control subjects and diabetic patients between 07.00 and 09.00 hours before breakfast and before each treatment, and then centrifuged at 164 x g for 10 rain as described previously [15] . The resulting supernatant (platelet-rich plasma) was centrifuged at 800 x g for 10 rain, washed, Lipid analysis: After the platelet suspension (490 gl) was incubated with 1 U/ml thrombin, 2 ml of chloroform/methanol/HCl (20: 40:1, v/v/v) [17] was added and lipid was then extracted by a modification of the Bligh-Dyer method [18] . Briefly, the resultant mixture was supplemented with 0.5 ml chloroform, mixed, and centrifuged at 2500 rev/min for 5 rain. The lower phase was collected and 0.5 ml of 0.2 tool/1 KC1-5 retool/1 EDTA mixture was added. The phases were separated by centrifugation, and the lower phase was collected and dried under nitrogen. The phosphoinositides were separated on HPTLC plates, and impregnated with 1% potassium oxalate in a solvent system of chloroform/acetone/methanol/acetic acid/water (40:15 : 13 : 12: [19] . The areas corresponding to individual lipids, identified by co-migration with authentic standards as indicated in Figure 2 , were scraped into vials and radioactivity was determined by a scintillation counter with toluene/Triton X-100/ water/2,2'-p-phenylene-bis(5-phenyloxazole)/2,5 diphenyloxazole (800 ml: 200 ml: 50 ml: 0.24 g: 3.3 g). The rate of radioactivity of each phospholipid was calculated.
Platelet aggregation: Platelet aggregation was achieved by Born's turbidimetric method [20] with an aggregometer (NBS Hema Tracer 801; NBS Niko Bioscience Inc., Tokyo, Japan). Briefly, 100 gl ofplatelet-rich plasma was stirred magnetically at 1100 rev/ min, 37 ~ C. After a 1 -min incubation, 0.25,0.3,0.5 or I U/ml bovine thrombin was added, and the change in light transmission was recorded for 7 min. The maximum aggregation was determined as the peak light transmission after addition of thrombin. . Data are expressed as mean _+ SEM of 23 diabetic subjects and 7 control subjects. 9 p < 0.05 i and 10 min. Reaction was terminated by the addition of sample buffer (150 mmol/1Tris/HC1, pH 6.8,7.5 % SDS, 12 % (v/v) glycerol, 4.5 % 2-mercaptoethanol), followed by placing in boiling water for 3 min. Samples were kept overnight at 4~ and then subjected to SDS-PAGE using 12.5 % acrylamide separating gels and 4.5 % stacking gels, both containing 0.1% SDS. The gels were dried and exposed to Kodak X-Omatic film for 72 h at -50 ~ to prepare autoradiographs. The intensity of phosphorylated protein was scanned with a laser densitometer (Pharmacia LKB Biotechnology, Tokyo, Japan) to determine the relative value.
Phosphorylation

Additional laboratory measurements:
Fasting blood glucose levels were determined by the glucose-oxidase method, and HbAlc levels were determined by HPLC. Cholesterol and triglycerides were assayed in the Central Biochemical Laboratory of Gifu University Hospital.
Statistical analysis
Statistical analysis was performed by Student's t-test. Statistical significance was defined asp less than 0.05. 
Results
Platelet aggregation in diabetic subjects: Low-dose (0.25 and 0.3 U/ml) thrombin-induced maximum aggregation in diabetic subjects was higher than in control subjects (0.25 U/ml; diabetic 65 + 4 % vs control subjects 8 + 4 %, 0.3 U/ml; diabetic 67 + 8 % vs control subjects 17 + 5%, p < 0.01). However, higher dose (0.5 and 1 U/ml) thrombin-induced maximum aggregation in diabetic subjects was similar to that in the control subjects (0.5 U/ml; diabetic 85 + 2% vs control subjects 89_+ 2%, 1 U/ml; diabetic 84 + 2% vs control subjects 89 + 5 %) (Fig.3) . Diabetic subjects were divided into three groups as indicated in Table1. Low-dose (0.25U/ml) thrombin-induced maximum aggregation in the sulphonylurea group and insulin group was significantly lower than in the diet group (0.25U/ml; diet 96_+2% vs insulin 58+13%, or sulphonylurea 41_+ 18%, p<0.05) (Fig.3) . However, thrombin-induced maximum aggregation in the insulin group was higher than that in control subjects.
Thrombin-induced phosphoinositide metabolism in diabetic and control subjects: As indicated in Figure 2 each phosphoinositide was separated by HPTLC. Figure 4) , and PA was increased by 60 s after stimulation with thrombin (1 U/ml) in both control and diabetic subjects. In this case, hydrolysis of PIP2 was increased in each diabetic subject compared to each control subject. Figure 5 shows that percent increases of PA were not significantly different from those in control subjects. However, percent increases of PA radioactivity in the insulin and sulphonylurea groups were lower than in the diet group 30 and 60 s after stimulation with 1 U/ml thrombin (at 60 s, diet group: 450 + 65 % vs sulphonylurea group: 264 + 42 % or insulin group: 245 + 35 %, p < 0.05-0.01). These results indicated that thrombin-induced phospholipase C activity in the insulin and sulphonylurea groups was lower than in the diet group. Thrombin-induced changes in each PIP2, PIP (diphosphoinositide:DPI) and PI radioactivity in the diabetic subjects were not significantly different from those in the control subjects. Moreover, there were no significant differences in thrombin-induced changes in PIP2 or PI radioactivity among the sulphonylurea, insulin and diet groups and control subjects (Figs. 4 and 6 ). However, thrombin-induced PIP hydrolysis in the sulphonylurea group was decreased compared with the diet group (at 10 s, sulphonylurea group: 111 +7% vs diet group: 99 + 4%) (Fig. 7) . These results indicated that thrombin-induced PIP-specific phospholipase C activity in the sulphonylurea group was decreased compared to that in the diet group. Each thrombin-induced phosphoinositide change (PA, PIPe, PI, and PIP) in the diet group was not significantly different from that in control subjects, respectively.
kDa protein phosphorylation in diabetic patients:
Thrombin-or TPA-stimulated phosphorylation of 47 kDa protein in diabetic subjects was not significantly different from that in the control subjects (Fig. 8) .
Moreover, there was no significant difference in thrombin-or TPA-induced 47 kDa protein phosphorylation among platelets from the diet, sulphonylurea insulin groups, respectively (thrombin stimulation at 1 min: diet 1725 _+ 1067 % n = 6, insulin 1435 + 280 % n = 12; sulphonylurea 1147 + 297 % n = 12, TPA stimulation at I rain: diet 1366 _+ 725 % n = 6, insulin 1206 + 253 % n = 12; sulphonylurea 1025 + 258 % n = 12; mean + SEM, control 100 %).
l;'ig.8. Studies and platelets phosphorylated by thrombin for 1 min and TPA for i and 10 min in a diabetic patient (right) and in a control subject (left)
Discussion
Thrombin-induced phosphoinositide metabolism and subsequent formation of diacylglycerol and protein kinase C activation are essential signal transduction mechanism(s) linked to platelet aggregation [21] [22] [23] . Several studies have been conducted to investigate the mechanism(s) responsible for the enhanced platelet responsiveness to aggregation and release-induced stimuli in both man and animals with diabetes [9, 10] . Most of these studies have focused on whether the arachidonic acid metabolism of platelets is altered in diabetes [11, 12, 24] . Recently, the breakdown of phosphoinositides has drawn attention as being the earliest even underlying the reactivity ofplatelets. Platelet shape change induced by thrombin is closely linked to phosphoinositide hydrolysis and may be independent of the liberation and metabolism of arachidonic acid [25] . We have already reported [15] enhanced hydrolysis of PIP2 by phospholipase C in platelets from diabetic subjects with microangiopathy as compared with control subjects. However, thrombin-induced phosphoinositide metabolismin platelets from untreated diabetic subjects has not been investigated. Thus, we have aimed to examine whether phosphoinositide metabolism in platelets from diabetic subjects behaves differently according to type of treatment. Moreover, we have shown that there are no significant differences between diet, sulphonylurea, and insulin groups in thrombin-induced 47 kDa protein phosphorylation [26] . Low-dose thrombin-stimulated platelet aggregation in diabetic patients was increased compared to control subjects, indicating that platelets from diabetic patients had been enhanced in thrombin-, ADP-, and collageninduced aggregation, consistent with previous reports 637 of in vivo and in vitro platelet activity [27] [28] [29] [30] [31] . Our data also indicate that thrombin-induced platelet aggregation in the insulin or sulphonylurea groups was decreased compared with the diet group. Although thrombin-induced PA formation, which is almost identical to phospholipase C activity, in the insulin and sulphonylurea groups was decreased compared with the diet group, no significant differences in thrombin-or TPA-induced 47 kDa protein phosphorylation between platelets from the three groups of diabetic patients were observed. The lack of an exact correlation between thrombin-induced phosphoinositide metabolism and thrombin-induced 47 kDa protein phosphorylation may have been due to the following: first, it may have been the result of influences of thrombin-stimulated phospholipase A2 activation on platelet aggregation and other platelet function(s). Secondly, PA synthesis generated by phospholipase C-and D-mediated hydrolysis of phosphatidylcholine [32, 33] and from the de novo pathway [34] may have been too complex. Thirdly, protein kinase C may have regulated phosphoinositide metabolism and Ca 2 + release from intracellular stores [26] ; finally, as each diabetic group was complicated with various types and grades of micro-and macroangiopathy, they may have been heterogenous.
These results suggest that sulphonylurea and insulin treatment suppress phospholipase C activity which hydrolyses polyphosphoinositides, generates diacylglycerol and induces PA formation in human platelets, and subsequently decreases platelet aggregation. Finally, we hypothesize that insulin and sulphonylurea treatments may affect phosphoinositide metabolism, protein phosphorylation and platelet aggregation and the development of diabetic complications.
